All In Biotech

Drug Trial Radar · NCT07257510

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

A Prospective, Multicenter Clinical Study of Pomalidomide Combined With Orelabrutinib and Zuberitamab in Treatment-Naive Mantle Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Aug 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Peking University Third HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter trial evaluates the efficacy and safety of pomalidomide combined with orelabrutinib and zuberitamab (POZ) in patients with mantle cell lymphoma (MCL). After six cycles of POZ, patients who achieved minimal residual disease (MRD) negativity received maintenance therapy with orelabrutinib plus zuberitamab for up to 18 cycles. Those with MRD positivity were excluded and received alternative treatments. The primary endpoint is the MRD rate after six cycles of POZ. Secondary endpoints include progression-free survival (PFS), overall survival (OS), MRD rate, objective response rate (ORR), and safety.

Conditions

  • Mantle Cell Lymphoma (MCL)
  • POZ

Interventions

  • PomalidomideDrug

    4mg/day PO once daily, day1-21/cycle

  • OrelabrutinibDrug

    150mg/day PO once daily

  • ZuberitamabDrug

    375 mg/m² IV on day 1/cycle

  • ZuberitamabDrug

    375 mg/m² IV on day 1 of cycle 7, 10, 13, 16, 19 and 22,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimum residual disease (MRD) rateTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.